The FDA is alerting pet owners and veterinarians of the potential for neurologic adverse events in dogs and cats when treated with drugs that are in the isoxazoline class.  They continue to monitor adverse drug event reports for these products and encourage pet owners and veterinarians to report such adverse drug events. 

These products can and have been safely used in the majority of dogs and cats, as stated on the FDA's "Fact Sheet for Pet Owners and Veterinarians" available at https://www.fda.gov/AnimalVeterinary/ResourcesforYou/AnimalHealthLiteracy/ucm620940.htm.  NYSVMS will be monitoring the development of this emerging issue, and will publicize any guidelines or policy statements as they become available from the AVMA or our own organization.